Researchers uncover a protective role of microRNA-26b in preventing MASH, a severe liver condition, and demonstrate how lipid nanoparticles can deliver targeted therapy.
Metabolic dysfunction-associated steatohepatitis (MASH), a more advanced form of fatty liver disease, is a growing global health concern with few effective treatment options. Now, a new study published in eLife brings hope for tackling the disease using a small RNA molecule known as microRNA-26b (miR-26b).
What is MASH?
MASH, previously grouped under the broader category of non-alcoholic fatty liver disease (NAFLD), involves liver fat accumulation, inflammation, and fibrosis. It’s closely linked to obesity, insulin resistance, and cardiovascular disease—and can progress to liver cirrhosis and cancer.
The Protective Role of miR-26b
Scientists from RWTH Aachen University, Maastricht University, and collaborators across Europe and China studied mice that lacked miR-26b and found they developed more severe symptoms of MASH:
-
Increased fat accumulation in the liver
-
Higher levels of inflammatory markers (such as TNF and IL-6)
-
Greater infiltration of immune cells
-
Accelerated liver fibrosis
In short, without miR-26b, the liver became more vulnerable to damage and inflammation.
Reversing the Damage: A Lipid Nanoparticle Breakthrough
To test whether restoring miR-26b could counteract these effects, the team used lipid nanoparticles (LNPs)—the same technology behind mRNA vaccines—to deliver synthetic miR-26b mimics into the liver.
The results were promising:
-
Hepatic cholesterol and lipid levels dropped
-
Inflammatory kinase activity was reduced
-
Some early fibrotic changes were reversed
Interestingly, these effects were not limited to mice. The same nanoparticles also reduced inflammation in human precision-cut liver slices, hinting at potential clinical relevance.
A New Path in Liver Disease Treatment
This study opens new doors in treating MASH by targeting miR-26b. It also underscores the broader potential of LNP-based RNA therapies in managing metabolic and inflammatory diseases.
Cosmael ThinkLab Commentary
This research stands at the intersection of molecular biology and translational medicine, highlighting how microRNA regulation and targeted delivery systems can influence chronic disease progression. The study’s use of human liver tissues for validation enhances its translational significance and exemplifies a future direction in personalized liver care.
Source:
Peters, L., Rakateli, L., et al. (2025). MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles. eLife, 13:RP97165. https://doi.org/10.7554/eLife.97165